Lynparza and Abraxane drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Lynparza (olaparib) and Abraxane (paclitaxel). Common drug interactions include metastases to bone among females and metastases to lung among males.

The phase IV clinical study analyzes what interactions people have when they take Lynparza and Abraxane. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Lynparza?

Lynparza has active ingredients of olaparib. eHealthMe is studying from 12,322 Lynparza users. Check the latest studies of Lynparza.

What is Abraxane?

Abraxane has active ingredients of paclitaxel. It is often used in breast cancer metastatic. eHealthMe is studying from 19,196 Abraxane users. Check the latest studies of Abraxane.

On Jul, 11, 2026

13 people who take Lynparza and Abraxane together, and have interactions are studied.

Lynparza and Abraxane drug interactions.

What are the common drug interactions of Lynparza and Abraxane, by gender? *:

female:

Metastases to bone (cancer spreads to bone)
Metastases to liver (cancer spreads to liver)
Metastases to lung (cancer spreads to lung)
Death
Cardiac failure
Cardiac failure chronic
Confusional state
Dyspepsia (indigestion)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Hypophagia (reduced food intake)

male:

Metastases to lung (cancer spreads to lung)
Metastases to lymph nodes (cancer spreads to lymph node)
Pruritus (severe itching of the skin)
Rash
Inflammation
Pyrexia (fever)
Malignant neoplasm progression (cancer tumour came back)
Tumour marker increased

What are the common drug interactions of Lynparza and Abraxane, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Malignant neoplasm progression (cancer tumour came back)
Metastases to bone (cancer spreads to bone)
Metastases to liver (cancer spreads to liver)
Metastases to lung (cancer spreads to lung)

40-49:

n/a

50-59:

Cardiomyopathy (weakening of the heart muscle)
Death
Cardiac failure
Cardiac failure chronic
Dyspepsia (indigestion)
Hypophagia (reduced food intake)
Ileus (a painful obstruction of the ileum or other part of the intestine)
Metastases to abdominal cavity (cancer spreads to abdominal cavity)
Renal disorder (kidney disease)

60+:

Metastases to lung (cancer spreads to lung)
Metastases to lymph nodes (cancer spreads to lymph node)
Pruritus (severe itching of the skin)
Rash
Inflammation
Pyrexia (fever)
Confusional state
Sepsis (a severe blood infection that can lead to organ failure and death)
Stomatitis (inflammation of mucous membrane of mouth)
Thrombocytopenia (decrease of platelets in blood)

What are the existing conditions these people have? *

Prostate Cancer: 3 people, 23.08%
Breast Cancer Female: 2 people, 15.38%
Pancreatic Carcinoma (pancreatic cancer): 1 person, 7.69%
Ovarian Epithelial Cancer (cancer that begins in the cells on the surface of the ovary): 1 person, 7.69%
Ill-Defined Disorder: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Lynparza and Abraxane?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously